Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer

Published:2023-08 Issue: Volume:189 Page:112919
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Han Ruoshuang,Guo Haoyue,Shi Jinpeng^ORCID,Wang Haowei,Zhao Sha,Jia Yijun,Liu Xiaozhen,Li Jiayu,Cheng Lei,Zhao Chao,Li Xuefei,Zhou Caicun^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference58 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

2. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

3. Lung cancer;Thai;Lancet,2021

4. Targeting the gatekeeper: osimertinib in EGFR T790M mutation-positive non-small cell lung cancer;Skoulidis;Clin Cancer Research,2017

5. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;New England J Med,2018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple myeloma exosomal miRNAs suppress cGAS-STING antiviral immunity;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-12

2. Bulk RNA analysis identified the characteristics and immunoinvasive patterns of osimertinib resistance in patients with non-small cell lung cancer;2024-09-11

3. Unveiling the contribution of tumor-associated macrophages in driving epithelial-mesenchymal transition: a review of mechanisms and therapeutic Strategies;Frontiers in Pharmacology;2024-09-02

4. Recent advances to address challenges in extracellular vesicle-based applications for lung cancer;Acta Pharmaceutica Sinica B;2024-09

5. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer;Journal of Clinical Oncology;2024-08-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3